pd-l1 peptide vaccine
Vaccineexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2017 (NCT03042793)
Timeline
Indications
Mechanism of action
- Programmed cell death 1 ligand 1Immunity, active
CD274 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pd-l1 peptide vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04051307 | Phase 1/Phase 2 (Phase 2) | Jul 10, 2019 | University of Copenhagen |
| NCT03850522 | Phase 2 | Feb 18, 2019 | IO Biotech, University of Copenhagen |
| NCT03714529 | Phase 2 | Nov 1, 2018 | University of Copenhagen |
| NCT03042793 | Phase 1 | Feb 1, 2017 | University of Copenhagen |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Copenhagen | Academic/Hospital | 4 | 4 | 2 | 2017 |
| IO Biotech | For profit | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1